Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

IIROC Trade Halt - Resverlogix Corp.

Newsfile October 13, 2017

Resverlogix Announces Annual and Special Meeting of Shareholders

GlobeNewswire October 2, 2017

Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

PR Newswire September 13, 2017

Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement

Canada NewsWire September 5, 2017

Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial

Canada NewsWire August 29, 2017

Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction

PR Newswire August 28, 2017

Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017

Canada NewsWire July 25, 2017

IIROC Trade Resumption - RVX

Canada NewsWire July 25, 2017

IIROC Trade Resumption - Resverlogix Corp.

Newsfile July 25, 2017

Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

Canada NewsWire July 25, 2017

IIROC Trading Halt - RVX

Canada NewsWire July 25, 2017

CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.

Newsfile July 25, 2017

IIROC Trade Halt - Resverlogix Corp.

Newsfile July 25, 2017

Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

PR Newswire July 10, 2017

Resverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical Trial

PR Newswire Asia July 10, 2017

Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

Canada NewsWire June 28, 2017

Resverlogix Comments on TSX Trader Notes

Canada NewsWire June 21, 2017

IIROC Trade Resumption - Resverlogix Corp.

Newsfile June 20, 2017

Resverlogix Closes $10 Million of Equity Subscriptions

Canada NewsWire June 20, 2017

IIROC Trade Halt - Resverlogix Corp.

Newsfile June 20, 2017